Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, B.
Right arrow Articles by Deckers, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, B.
Right arrow Articles by Deckers, P.

Journal of Clinical Oncology, Vol 15, 1858-1869, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

B Fisher, S Anderson, DL Wickerham, A DeCillis, N Dimitrov, E Mamounas, N Wolmark, R Pugh, JN Atkins, FJ Meyers, N Abramson, J Wolter, RS Bornstein, L Levy, EH Romond, V Caggiano, M Grimaldi, P Jochimsen and P Deckers

PURPOSE: The National Surgical Adjuvant Breast and Bowel Project (NSABP) initiated a randomized trial (B-22) to determine if intensifying but maintaining the total dose of cyclophosphamide (Cytoxan, Bristol-Myers Squibb Oncology, Princeton, NJ) in a doxorubicin (Adriamycin, Pharmacia, Kalamazoo, MI)-cyclophosphamide combination (AC), or if intensifying and increasing the total dose of cyclophosphamide improves the outcome of women with primary breast cancer and positive axillary nodes. PATIENTS AND METHODS: Patients (N = 2,305) were randomized to receive either four courses of standard AC therapy (group 1); intensified therapy, in which the same total dose of cyclophosphamide was administered in two courses (group 2); or intensified and increased therapy, in which the total dose of cyclophosphamide was doubled (group 3). The dose and intensity of doxorubicin were similar in all groups. Disease-free survival (DFS) and overall survival were determined using life-table estimates. RESULTS: There was no significant difference in DFS (P = .30) or overall survival (P = .95) among the groups through 5 years. At 5 years, the DFS of women in group 1 was similar to that of women in group 2 (62% v 60%, respectively; P = .43) and to that of women in group 3 (62% v 64%, respectively; P = .59). The 5-year survival of women in group 1 was similar to that of women in group 2 (78% v 77%, respectively; P = .86) and to that of women in group 3 (78% v 77%, respectively; P = .82). Grade 4 toxicity increased in groups 2 and 3. Failure to note a difference in outcome among the groups was unrelated to either differences in amount and intensity of cyclophosphamide or to dose delays and intervals between courses of therapy. CONCLUSION: Intensifying or intensifying and increasing the total dose of cyclophosphamide failed to significantly improve either DFS or overall survival in any group. It was concluded that, outside of a clinical trial, dose-intensification of cyclophosphamide in an AC combination represents inappropriate therapy for women with primary breast cancer.


This article has been cited by other articles:


Home page
 JCOHome page
S. A. Cannistra
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
J. Clin. Oncol., August 1, 2008; 26(22): 3665 - 3667.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. Findlay, K. Tonkin, M. Crump, B. Norris, M. Trudeau, M. Blackstein, M. Burnell, J. Skillings, D. Bowman, D. Walde, et al.
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes
Ann. Onc., October 1, 2007; 18(10): 1646 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al.
Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623
J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al.
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann. Onc., April 1, 2007; 18(4): 694 - 700.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. M. Linden, C. M. Haskell, S. J. Green, C. K. Osborne, G. W. Sledge Jr, C. L. Shapiro, J. N. Ingle, D. Lew, L. F. Hutchins, R. B. Livingston, et al.
Sequenced Compared With Simultaneous Anthracycline and Cyclophosphamide in High-Risk Stage I and II Breast Cancer: Final Analysis From INT-0137 (S9313)
J. Clin. Oncol., February 20, 2007; 25(6): 656 - 661.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Jones, M. A. Savin, F. A. Holmes, J. A. O'Shaughnessy, J. L. Blum, S. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. Kirby, et al.
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
J. Clin. Oncol., December 1, 2006; 24(34): 5381 - 5387.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Hudis and E. P. Winer
Cancer and leukemia group B breast committee: decades of progress and plans for the future.
Clin. Cancer Res., June 1, 2006; 12(11): 3576s - 3580s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. L. Wapnir, S. J. Anderson, E. P. Mamounas, C. E. Geyer Jr, J.-H. Jeong, E. Tan-Chiu, B. Fisher, and N. Wolmark
Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials
J. Clin. Oncol., May 1, 2006; 24(13): 2028 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Venturini, L. Del Mastro, E. Aitini, E. Baldini, C. Caroti, A. Contu, F. Testore, F. Brema, P. Pronzato, G. Cavazzini, et al.
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
J Natl Cancer Inst, December 7, 2005; 97(23): 1724 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist, November 1, 2005; 10(10): 766 - 779.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al.
Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort
J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Arpino, H.L. Weiss, G.M. Clark, S.G. Hilsenbeck, and C.K. Osborne
Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen
J. Clin. Oncol., July 20, 2005; 23(21): 4687 - 4694.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Howell and A. M Wardley
Overview of the impact of conventional systemic therapies on breast cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S9 - S16.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. S McCune, D. M Games, and J. L Espirito
Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors
Journal of Oncology Pharmacy Practice, June 1, 2005; 11(2): 37 - 43.
[Abstract] [PDF]

Home page
 JCOHome page
E. P. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S. M. Sedlacek, B. Fisher, D. L. Wickerham, G. Yothers, A. Soran, and N. Wolmark
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28
J. Clin. Oncol., June 1, 2005; 23(16): 3686 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. J. Pierce
The Use of Radiotherapy After Mastectomy: A Review of the Literature
J. Clin. Oncol., March 10, 2005; 23(8): 1706 - 1717.
[Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 JCOHome page
A. Taghian, J.-H. Jeong, E. Mamounas, S. Anderson, J. Bryant, M. Deutsch, and N. Wolmark
Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials
J. Clin. Oncol., November 1, 2004; 22(21): 4247 - 4254.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Dang, G. M. D'Andrea, M. E. Moynahan, M. N. Dickler, A. D. Seidman, M. Fornier, M. E. Robson, M. Theodoulou, D. Lake, V. E. Currie, et al.
Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5754 - 5761.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Mandelblatt, C. B. Schechter, K. R. Yabroff, W. Lawrence, J. Dignam, P. Muennig, Y. Chavez, J. Cullen, and M. Fahs
Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women
J. Clin. Oncol., July 1, 2004; 22(13): 2554 - 2566.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, D. A. Berry, S. Woolf, D. Duggan, A. Kornblith, L. N. Harris, R. A. Michaelson, J. A. Kirshner, G. F. Fleming, M. C. Perry, et al.
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
J. Clin. Oncol., June 1, 2004; 22(11): 2061 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Stearns and N. E. Davidson
Deja Vu for Breast Cancer Two?
J Natl Cancer Inst, April 7, 2004; 96(7): 497 - 499.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. M. Swain, J. W. Wilson, E. P. Mamounas, J. Bryant, D. L. Wickerham, B. Fisher, S. Paik, and N. Wolmark
Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer
J Natl Cancer Inst, April 7, 2004; 96(7): 516 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
E. P. Mamounas
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clin. Med. Res., October 1, 2003; 1(4): 309 - 326.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Crump, D. Tu, L. Shepherd, M. Levine, V. Bramwell, and K. Pritchard
Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., August 15, 2003; 21(16): 3066 - 3071.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Trent, V. Valero, D. J. Booser, L. T. Esparza-Guerra, N. Ibrahim, Z. Rahman, L. Vernillet, S. Patel, C. L. David, J. L. Murray, et al.
A Phase I Study of Docetaxel Plus Cyclophosphamide in Solid Tumors followed by a Phase II Study as First-Line Therapy in Metastatic Breast Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2426 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Marchetti, K. Cannita, E. Ricevuto, F. De Galitiis, Z. C. Di Rocco, A. Tessitore, R. Bisegna, G. Porzio, G. P. De Rubeis, T. Ventura, et al.
Prognostic value of p53 molecular status in high-risk primary breast cancer
Ann. Onc., May 1, 2003; 14(5): 704 - 708.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson
Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience
J. Clin. Oncol., April 1, 2003; 21(7): 1195 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. C. Henderson, D. A. Berry, G. D. Demetri, C. T. Cirrincione, L. J. Goldstein, S. Martino, J. N. Ingle, M. R. Cooper, D. F. Hayes, K. H. Tkaczuk, et al.
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 976 - 983.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al.
Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial
J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Stearns, B. Singh, T. Tsangaris, J. G. Crawford, A. Novielli, M. J. Ellis, C. Isaacs, M. Pennanen, C. Tibery, A. Farhad, et al.
A Prospective Randomized Pilot Study to Evaluate Predictors of Response in Serial Core Biopsies to Single Agent Neoadjuvant Doxorubicin or Paclitaxel for Patients with Locally Advanced Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 124 - 133.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. L. Du, C. Osborne, and J. S. Goodwin
Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer
J. Clin. Oncol., December 15, 2002; 20(24): 4636 - 4642.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Ellis, R. B. Livingston, J. R. Gralow, S. J. Green, and T. Thompson
Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer
J. Clin. Oncol., September 1, 2002; 20(17): 3637 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters
Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
National Institutes of Health Consensus Developmen
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
J. J. Dignam
Efficacy of Systemic Adjuvant Therapy for Breast Cancer in African-American and Caucasian Women
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 36 - 43.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. Goldhirsch, R. D. Gelber, G. Yothers, R. J. Gray, S. Green, J. Bryant, S. Gelber, M. Castiglione-Gertsch, and A. S. Coates
Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored Treatments
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 44 - 51.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
M. J Piccart, C. Lohrisch, L. Duchateau, and M. Buyse
Taxanes in the Adjuvant Treatment of Breast Cancer: Why Not Yet?
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 88 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Fornier, A. D. Seidman, M. Theodoulou, M. E. Moynahan, V. Currie, M. Moasser, N. Sklarin, T. Gilewski, G. D'Andrea, R. Salvaggio, et al.
Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma
Clin. Cancer Res., December 1, 2001; 7(12): 3934 - 3941.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. H. Partridge, H. J. Burstein, and E. P. Winer
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 135 - 142.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Tagnon, F. Ries, P. Gobert, C. Finet, et al.
Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer
J. Clin. Oncol., June 15, 2001; 19(12): 3103 - 3110.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al.
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology
J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. N. Levine and A. Eisen
Anthracycline Adjuvant Chemotherapy: How Much Is Enough?
J. Clin. Oncol., February 1, 2001; 19(3): 599 - 601.
[Full Text] [PDF]

Home page
 JCOHome page
Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial
J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Fumoleau, F. Chauvin, M. Namer, R. Bugat, M. Tubiana-Hulin, J. P. Guastalla, T. Delozier, P. Kerbrat, Y. Devaux, J. Bonneterre, et al.
Intensification of Adjuvant Chemotherapy: 5-Year Results of a Randomized Trial Comparing Conventional Doxorubicin and Cyclophosphamide With High-Dose Mitoxantrone and Cyclophosphamide With Filgrastim in Operable Breast Cancer With 10 or More Involved Axillary Nodes
J. Clin. Oncol., February 1, 2001; 19(3): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Katz, E. A. Strom, T. A. Buchholz, H. D. Thames, C. D. Smith, A. Jhingran, G. Hortobagyi, A. U. Buzdar, R. Theriault, S. E. Singletary, et al.
Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation
J. Clin. Oncol., August 15, 2000; 18(15): 2817 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Basser, C. Underhill, I. Davis, M. D. Green, J. Cebon, J. Zalcberg, J. MacMillan, B. Cohen, J. Marty, R. M. Fox, et al.
Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer
J. Clin. Oncol., August 15, 2000; 18(15): 2852 - 2861.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Lippman
High-Dose Chemotherapy plus Autologous Bone Marrow Transplantation for Metastatic Breast Cancer
N. Engl. J. Med., April 13, 2000; 342(15): 1119 - 1120.
[Full Text]

Home page
 The OncologistHome page
W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes
High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer
Oncologist, February 1, 2000; 5(1): 1 - 13.
[Abstract] [Full Text]

Home page
 JCOHome page
B. Fisher, S. Anderson, A. DeCillis, N. Dimitrov, J. N. Atkins, L. Fehrenbacher, P. H. Henry, E. H. Romond, K. S. Lanier, E. Davila, et al.
Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25
J. Clin. Oncol., November 1, 1999; 17(11): 3374 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. N. Hortobagyi
High-Dose Chemotherapy for Primary Breast Cancer: Facts Versus Anecdotes
J. Clin. Oncol., November 1, 1999; 17(90001): 25 - 29.
[Full Text] [PDF]

Home page
 JCOHome page
K. H. Antman
Critique of the High-Dose Chemotherapy Studies in Breast Cancer: A Positive Look at the Data
J. Clin. Oncol., November 1, 1999; 17(90001): 30 - 34.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. W. Hu, G. D. Long, K. E. Stockerl-Goldstein, L. J. Johnston, N. J. Chao, R. S. Negrin, and K. G. Blume
A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer
Clin. Cancer Res., November 1, 1999; 5(11): 3411 - 3418.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. J. Gradishar
High-Dose Chemotherapy and Breast Cancer
JAMA, October 13, 1999; 282(14): 1378 - 1380.
[Full Text] [PDF]